The TOP20 global pharmaceutical companies are reshuffled!

Compared with 2020, when the epidemic is raging, none of the top 20 pharmaceutical companies in 2021 will have a decline in revenue, and most companies will even increase by more than 5%

According to FiercePharma statistics, among the top 20 companies with total revenue in 2021, the lowest increase is 2% and the highest is 3836%.

In addition, it is worth noting that Biogen, which fell off the list, suffered an 18% drop in revenue because sales of the controversial Alzheimer's disease drug Aduhelm fell short of expectations

01 Johnson & Johnson

2021 revenue: $93.

2020 revenue: $82.

Johnson & Johnson has maintained its top spot since 2019, with global revenue of $93.

Among them, the pharmaceutical business brought in US$52 billion in revenue, an increase of 13.

Ustekinumab, with sales exceeding $9 billion in 2021, is expected to become the next super-blockbuster, and daratumumab is the drug with the greatest growth potential, with sales exceeding $6 billion, an increase from 2020 44%

But whether J&J will remain No.

02 Pfizer

2021 revenue: $81.

2020 revenue: $41.

While Pfizer is relying on a new crown vaccine and oral new crown drugs to grab the top spot in 2021, 2022 is not necessarily

Also, even excluding anti-coronavirus products, Pfizer's full-year revenue rose 6% last year to nearly $45 billion

But Pfizer's existing business is also at risk of a decline and patent expiry, with its pneumococcal vaccine Peer slumping by double digits in the fourth quarter of 2021

03 Roche

2021 revenue: CHF 62.

2020 revenue: CHF 58.

In 2021, the patent cliff faced by Roche is still severe.
Its troika rituximab, trastuzumab and bevacizumab have fallen by more than 4 billion Swiss francs due to the patent cliff.
Roche also expects that in 2022 Will fall another 2.
5 billion Swiss francs
.

But Roche is shifting its focus to new medicines, with sales of medicines rising 3% in constant currency last year to 45 billion Swiss francs
.
The largest share of the growth came from multiple sclerosis drug Ocrevus, hemophilia drug Hemlibra, inflammatory disease treatment Actemra and PD-L1 inhibitor Tecentriq
.

In terms of research and development, Roche's SMA oral drug Evrysdi, ophthalmic drug Vabysmo and beta-amyloid antibody gantenerumab have attracted much attention
.
Among them, Evrysdi is the first FDA-approved oral drug for SMA for the treatment of infants and adults with SMA aged two months and older
.

04 AbbVie

2021 revenue: $56.
2 billion

2020 revenue: $45.
8 billion

After AbbVie's unremitting efforts, Humira's sales finally reached $20.
7 billion in 2021, accounting for nearly 40% of AbbVie's total revenue.
Last year, AbbVie's total revenue was $56.
2 billion, a year-on-year increase of 22%
.

But AbbVie also has to prepare for an impending patent cliff, with Humira's first biosimilar hitting the U.
S.
market in 2023
.

In terms of product marketing, AbbVie has set its sights on products like the Rinvoq and Skyrizi, which it expects to generate $15 billion in revenue by 2025
.
In 2019, AbbVie also spent $63 billion to acquire Allergan, leaping into the global pharmaceutical TOP5
.

In addition, AbbVie is also actively expanding its blood oncology business.
In 2021, the revenue of blood oncology products will be US$7.
228 billion, accounting for 14%.
Among them, Venclexta’s sales revenue will reach US$1.
82 billion in 2021, a year-on-year increase of 36.
1%
.

05 Novartis

2021 revenue: $51.
6 billion

2020 revenue: $48.
66 billion

Novartis' total revenue in 2021 is $51.
6 billion, a year-on-year increase of 6%, with the main growth drivers coming from anti-inflammatory biologic Cosentyx and heart drug Entresto, with sales of $4.
72 billion and $3.
55 billion, respectively
.
Sales of the latter have grown by 40% annually, and Novartis expects annual peak sales of Entresto to exceed $5 billion, but Novartis is already working on a protection plan for its patent expiry in 2025
.

In addition, Novartis' blockbuster SMA gene therapy Zolgensma, in its third year on the market, has sales climbed 47% to $1.
35 billion in 2021, and is conducting clinical trials for the indication of elderly patients
.

FiercePharma expects Novartis' mergers and acquisitions to take center stage in 2022
.
Novartis will reap abundant cash flow after the $10 billion sale of Roche shares and the planned sale of Sandoz
.

06 Merck & Co.

2021 revenue: $48.
7 billion

2020 revenue: $48 billion

FiercePharma rated Merck's revenue growth in 2021 as no small feat, as Merck completed the spin-off of its women's health and generics businesses during the year to form Organon
.

Merck's main growth last year came from a boost in new crown oral drugs and increased sales of blockbuster drugs
.
Although the new crown oral drug Molnupiravir was only approved in the fourth quarter, the pre-sale agreement helped its sales in the fourth quarter to reach 952 million US dollars
.

And the super-blockbuster PD-1 inhibitor K drug also shouldered the burden, with sales increasing 20% ​​from $14.
4 billion to $17.
2 billion
.
The 9-valent HPV vaccine also brought in $5.
7 billion, a 44% increase from the previous year's $3.
9 billion figure
.

Merck predicts that the peak sales of its new crown oral drug Molnupiravir will reach 5 billion to 6 billion US dollars; and K drug is also expected to become the world's best-selling drug after the new crown epidemic subsides
.

07 BMS

2021 revenue: $46.
4 billion

2020 revenue: $42.
5 billion

BMS is also in an important transition period.
BMS’s revenue last year was US$46.
4 billion, of which US$12.
82 billion, accounting for 27.
6%, came from lenalidomide obtained from the acquisition of Celgene
.
In immuno-oncology, Opdivo generated $7.
52 billion in sales in 2021, up 8%, while Yervoy fell $2 billion, up 20%
.

BMS expects global lenalidomide sales to reach US$9.
5 billion to US$10 billion in 2022, and is expected to decline by US$2 billion to US$2.
5 billion annually thereafter
.

BMS hopes to fill this gap with a series of new products, BMS entered the field of cell therapy in 2021, and its CD19-targeting CAR-T cell therapy Breyanzi received FDA approval for the treatment of two or more systemic therapies.
of adult patients with relapsed or refractory large B-cell lymphoma
.
In early 2022, Abecma, the world's first BCMA CAR-T cell therapy, was also approved for marketing
.

BMS expects to generate $45 billion to $50 billion in free cash flow over the next three years, which will be used for business expansion
.

08 GSK

2021 revenue: £34.
114 billion ($44.
42 billion)

2020 revenue: £34.
099 billion ($43.
78 billion)

In 2021, GSK's revenue is 34.
114 billion pounds.
According to FiercePharma analysis, GSK's performance growth in 2021 is attributed to Vir Biotech's antibody therapy Sotrovimab
.

On May 28, 2021, the Sotrovimab new crown neutralizing antibody therapy received contraindication authorization from the US FDA for the treatment of mild and moderate symptoms of the new crown in people 12 years of age and older
.
However, on April 5 this year, the FDA announced that it was no longer authorized for the treatment of new crowns in the United States.
This was due to the increase in new crown cases caused by the BA.
2 subvariant of Omicron, and the data showed that Sotrovimab therapy was effective on the BA.
2 subvariant.
Physical utility is not great
.

GSK has two other drugs that are blockbusters in 2021
.
Trelegy, which treats asthma and chronic obstructive pulmonary disease, generated sales of £1.
2 billion ($1.
6 billion), while Nucala, which treats asthma, brought in £1.
14 ($1.
5 billion)
.

After spinning off its $10 billion consumer healthcare business, GSK is stepping up the development of new vaccines and innovative drug products, which it expects to return to $46 billion in 2031
.

09 Sanofi

2021 revenue: €37.
76 billion ($43.
12 billion)

2020 revenue: €36.
04 billion ($39.
3 billion)

Benefiting from killing two birds with one stone, the blockbuster immune product Dupixent and the vaccine business, Sanofi’s full-year sales in 2021 increased by 7.
1% to 37.
76 billion euros.
Sanofi’s expectation for the peak sales of Dupixent is more than 13 billion euros (about $14.
44 billion)
.

Sanofi has launched a series of clinical trials around Dupixent in the field of immunology.
Among the clinical pipelines disclosed by Sanofi, there are 8 phase 3 clinical trials and 1 phase 2 clinical trial involving dupilumab
.
Expanding to the immune science sector, there are nearly 30 clinical trials in Phases 1-3, which is close to one-third of Sanofi's total clinical trials
.

10 AstraZeneca

2021 revenue: $37.
42 billion

2020 revenue: $26.
62 billion

Following the completion of the $39 billion acquisition of Alexion, AZ received a huge boost in 2021 revenue with $37.
42 billion in revenue, an increase of nearly $10 billion from $26.
62 billion in 2020
.

The C5 inhibitors Soliris and Ultomiris, acquired from Alexion, added $3.
1 billion to AZ's revenue last year, and sales of both drugs rose 8% from the same period in 2020
.

Aside from rare diseases, AZ's largest oncology product accounted for the lion's share of the growth
.
Four blockbuster drugs, EGFR inhibitor Tagrisso, PD-L1 inhibitor Imfinzi, Merck's PARP inhibitor Lynparza and BTK inhibitor Calquence, all ended the fourth quarter with double-digit sales growth
.

However, AZ's performance in China was affected by the pricing of medical insurance negotiations and volume purchases, with revenue of US$6.
011 billion, a year-on-year increase of only single digits
.
AZ also expects revenue in China to fall by around 5% in 2022
.

11 Takeda

2021 revenue: $31.
55 billion

2020 revenue: $29.
25 billion

Takeda CEO Christophe Weber has been calling 2021 a "turning year" for the company, in which Takeda hopes to advance its late-stage pipeline and launch several new drugs
.

Over the past year, Takeda has narrowed its focus by selling "non-core" assets and paying down debt from its massive Shire acquisition
.
At present, Takeda's best-selling drug is Entyvio, a drug for inflammatory bowel disease, which is the main growth engine for its performance growth
.
The drug's sales in the first three quarters of last year reached 395.
4 billion yen, a year-on-year increase of 23.
8%
.

In the company's announcement of the third quarter of fiscal 2021, Costa Saroukos, Chief Financial Officer of Takeda Pharmaceuticals, said that in the future, Takeda remains committed to continuing to invest in the company's 14 global brands and innovative pipelines covering approximately 40 clinical-stage assets in order to achieve revenue in the next ten years.
growth
.

Takeda has Wave1 and Wave2 plans, a five-year plan and a ten-year plan, in its R&D pipeline
.
Wave1's goal is to achieve short-term growth and expand the global brand
.
In 2021, some of Wave1's products have been successfully launched
.
Last November, Takeda's CMV drug Livtencity received FDA approval to treat patients with cytomegalovirus (CMV) infection after transplantation in adults or children 12 years or older
.
The Livtencity approval also marks the second approval for Takeda's Wave1 pipeline, which also includes more than a dozen drugs and vaccines the company hopes to launch by fiscal 2024
.
The company received conditional approval from the U.
S.
FDA in September this year for the prior treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations
.

12 Lilly

2021 revenue: $28.
32 billion

2020 revenue: $24.
54 billion

Lilly's total revenue for the full year 2021 was $28.
32 billion, a year-on-year increase of 15%
.
R&D investment was US$7.
026 billion, an increase of 15%
.

The GLP-1 receptor agonist dulaglutide (Trulicity) is Eli Lilly's current ace product, and will continue to maintain a stable and rapid growth of more than 20% in 2021, with sales revenue reaching US$6.
472 billion
.
Indicated for glycemic control in adults with type 2 diabetes mellitus, including monotherapy and in patients with poor glycemic control despite metformin and/or sulfonylurea therapy
.

Lilly's current business mainly focuses on four major disease areas: diabetes, tumor, immunity and neurology
.
Diabetes business has always been Lilly’s dominant and key layout direction.
The combined contribution of eight product portfolios including Trulicity (dulaglutide), Humulin (recombinant human insulin), Humalog (insulin lispro), and Jardiance (empagliflozin) Revenue of $13.
188 billion accounted for 46.
6% of Lilly's total revenue
.

Oncology is the second largest segment of Lilly's revenue, contributing $5.
741 billion to Lilly
.
A total of three anti-tumor products have sales of over US$1 billion, namely Alimta (pemetrexed) with sales of US$2.
061 billion, Verzenio (Abexili) with sales of US$1.
35 billion, and Cyramza (remuciridine) with US$1.
033 billion.
resistance)
.

Eli Lilly expects 2022 sales to be between $27.
8 billion and $28.
3 billion
.

13 Bayer

2021 revenue: $28.
23 billion

2020 revenue: $25.
71 billion

From 2016 to 2018, Bayer's pharmaceutical industry sales topped 25 billion euros ($27.
8 billion) each year, but began to decline after 2018
.
Bayer has struggled since buying Monsanto for $63 billion
.
Forced to sell assets in multiple industries
.
The asset sell-off also led to a sharp drop in Bayer's pharmaceutical industry revenue, from €25.
32 billion ($28.
39 billion) in 2018 to €23.
71 billion ($26.
49 billion) in 2019 and €22.
56 billion ($25.
71 billion) in 2020 )
.

However, in 2021, Bayer achieved a reversal
.
Bayer achieved revenue of 23.
87 billion euros in 2021, with sales up 10 percent
.

In 2021, Bayer's top three best-selling drugs are rivaroxaban, aflibercept, and Mirena (Mirena IUD)
.
Among them, two drugs, rivaroxaban and aflibercept, account for half of Bayer's performance
.

The oral anticoagulant drug rivaroxaban, jointly developed by Bayer and Johnson & Johnson, remains the top-performing product in 2021
.
According to the financial reports of the two companies, rivaroxaban’s global sales in 2021 will reach US$8 billion, and Bayer is responsible for rivaroxaban’s markets outside the United States
.
The continued high volume in China and Russia offset the impact of the price reduction of this product in China, and rivaroxaban brought Bayer 4.
735 billion euros in revenue with a growth of 4.
87%
.
The patent of rivaroxaban in China has expired in 2020.
In addition, the patent of rivaroxaban will expire in EU countries in 2023, in the United States in 2024, and in Japan in 2025
.

The sales of ophthalmic drug aflibercept also achieved substantial growth, reaching 2.
918 billion euros, a year-on-year increase of 18.
23%
.
According to Regeneron’s financial report, Aflibercept’s U.
S.
market revenue is US$5.
792 billion.
At present, the global revenue of this blockbuster has reached US$9.
385 billion, a year-on-year increase of 19%.
It is expected to exceed US$10 billion in 2022
.

14 Gilead

2021 revenue: $27.
3 billion

2020 revenue: $24.
7 billion

Gilead's total revenue for the full year 2021 was $27.
3 billion, an increase of 11% year-over-year
.
R&D investment was US$5.
363 billion, a year-on-year increase of 6.
4%
.
Among them, the sales revenue of Remdesivir will increase by 98% in 2021, reaching US$5.
56 billion
.

From the perspective of business performance in various disease areas, HIV sales revenue was US$16.
3 billion, down 4%; HCV sales revenue was only nearly US$1.
9 billion for the whole year, continuing to decline; HBV and HDV business grew by 13% in 2021, reaching 9.
69% billion dollars in revenue
.
Cell therapy sales revenue continued to grow rapidly and steadily, reaching $871 million, up 43%
.

HIV drugs represented by Bitovavir and Lenacapavir are the core pillars of Gilead
.
The three-in-one HIV drug Bitovi is the core pillar product of Gilead's growth, with sales revenue of US$8.
624 billion in 2021, a year-on-year increase of 19%
.

In 2021, Gilead's oncology business will also achieve revenue of more than $1 billion, becoming a new growth area for the company, while the cell therapy field is Gilead's strategic high ground in the oncology field
.
Akilence's sales in 2021 were $690 million, an increase of 23% from last year; Tecartus also achieved $170 million in sales in its first full fiscal year
.

Gilead said that in 2022, the company will once again usher in an important node for key products, including Trodelvy, Akilence and Lenacapavir, which is expected to continue to expand its product advantages
.

15 Amgen

2021 revenue: $25.
98 billion

2020 revenue: $25.
42 billion

Amgen's total revenue for the year was $25.
98 billion, with full-year product sales in the U.
S.
down 4% and full-year product sales outside the U.
S.
up 12%, including a 36% increase in Asia Pacific
.
Amgen's full-year R&D expenses were US$4.
819 billion, a year-on-year increase of 15%, accounting for 18.
5% of total revenue
.

Robert A.
Bradway, chairman and chief executive officer of Amgen, said: "Over the past year, many of our key products have achieved strong sales growth
.
" Amgen's main business is divided into biosimilars and innovative drugs
.
Etanercept for rheumatic immunity contributed $4.
465 billion, denosumab contributed $2.
018 billion, and PCSK9 Repatha contributed $1.
117 billion
.

In terms of products, Amgen has launched five biosimilars, including: Amgevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), Avsola (infliximab) anti) and Riabn (rituximab)
.
Among them, adalimumab and bevacizumab performed better in the market
.
In 2021, adalimumab will achieve sales of US$439 million, a year-on-year increase of 33%.
Adalimumab is still the most prescribed adalimumab biosimilar in Europe
.
Bevacizumab achieved sales of US$1.
166 billion, a year-on-year increase of 46%
.

16 Boehringer Ingelheim

2021 revenue: $24.
36 billion

2020 revenue: $22.
29 billion

In 2021, Boehringer Ingelheim's R&D investment will once again hit a record high in the company's 137-year history
.
Total R&D expenditure reached EUR 4.
1 billion, an increase of 11.
7% year-on-year
.
R&D investment in the Human Medicines business increased to 3.
7 billion euros, while R&D investment in the Animal Health business increased by 1% to 416 million euros
.

In 2021, Boehringer Ingelheim's net sales will reach 20.
6 billion euros, and all three business areas have made positive contributions to the company's growth in net sales and operating income
.
Among them, the net sales of the human medicine business reached 15.
3 billion euros, an increase of 8.
4% year-on-year, accounting for 74% of the total net sales
.
Drugs used to treat cardiovascular, metabolic and respiratory diseases continued to be the most important contributors to net sales
.
Ou Tangjing remained the top contributor to revenue from the Human Medicines business, with net sales reaching 3.
9 billion euros, a year-on-year increase of 28.
6%
.
Vigart was the second largest contributor to the company's revenue, with net sales reaching 2.
5 billion euros, a year-on-year increase of 25.
4%
.

At present, the human drug R&D pipeline includes more than 100 clinical and preclinical projects, and as many as 15 new products are expected to be approved for marketing by 2025
.
Boehringer Ingelheim expects net sales to rise "slightly" year-on-year in 2022
.
The company expects to invest 25 billion euros in research and development over the next five years
.
As many as 15 of the company's drugs could be approved by 2025
.

17 Novo Nordisk

2021 revenue: $22.
38 billion

2020 revenue: $20.
24 billion

While the epidemic continues to rage, Novo Nordisk has maintained steady growth
.

Novo Nordisk's share of the global diabetes market has increased from 29.
3% in 2020 to 30.
1%, and Novo Nordisk aims to gain a third of the global diabetes market by 2025
.

At present, Novo Nordisk’s sales in the field of diabetes are mainly driven by GLP-1 drugs.
In fiscal 2021, Novo Nordisk’s GLP-1 product revenue totaled DKK 53.
597 billion.
GLP-1 products are used throughout the company’s diabetes The proportion of the pharmaceutical market increased to 26.
5% from 21.
9% 12 months ago
.
The current GLP-1 product portfolio of Novo Nordisk in the hypoglycemic field includes Victoza® (liraglutide injection), Ozempic® (semaglutide injection) and Rybelsus® (oral semaglutide)
.

In the field of weight loss, Novo Nordisk's GLP-1 products include Saxenda® (liraglutide injection) and Wegovy® (weekly semaglutide injection, 2.
4 mg strength)
.
The above two products will contribute 8.
4 billion Danish kroner (about 1.
283 billion US dollars) in revenue in 2021, a year-on-year increase of 50%
.
If the above two GLP-1 drugs in the weight loss field are calculated, Novo Nordisk's GLP-1 drugs will contribute a combined revenue of US$9.
5 billion in 2021, or nearly US$10 billion
.

18 BioNTech

2021 revenue: $22.
44 billion

2020 revenue: $549 million

The mRNA new crown vaccine has allowed BioNTech to achieve a 3836% increase in its performance in 2021
.

BioNTech achieved operating income of US$22.
44 billion in 2021 and delivered approximately 2.
6 billion doses of the new crown vaccine COMIRNATY/BNT162b2 to more than 165 countries and regions around the world
.
Signed orders for Covid-19 vaccine delivered in 2022 increase to 2.
4 billion doses
.
2022 new crown vaccine revenue is expected to be 13-17 billion euros (14.
4-18.
8 billion US dollars)
.

BioNTech has begun expanding Phase III clinical trials, including Omicron-based vaccine candidates, and has expanded its mRNA vaccine pipeline to address high-demand infectious diseases through multiple preclinical programs, which are expected to enter in 2022 clinical
.
Separately, the company expects to approve a share repurchase program of up to $1.
5 billion over the next two years
.

19 Moderna

2021 revenue: $18.
47 billion

2020 revenue: $803 million

Over the past year, Moderna's global revenue was $18.
47 billion, a 2,200% increase from 2020
.

Before the COVID-19 pandemic, few outside the biopharmaceutical industry knew about Moderna, an mRNA company founded in 2010
.
But that all changed as the company took a leadership role in global vaccination efforts
.

As Moderna's only product right now, the COVID-19 vaccine Spikevax contributes the vast majority of the company's total revenue -- $17.
7 billion
.
Moderna said this came from sales of 807 million doses of the vaccine, about 25% of which were used in low- and middle-income countries
.
Moderna expects to continue expanding in 2022 to help end the COVID-19 pandemic
.

Currently, Moderna has 44 mRNA pipelines in development, including an Omicron-specific COVID-19 vaccine
.
Moderna is likely to remain among the pharmaceutical giants as Moderna develops and launches products other than Spikevax in the future
.
20

Huizhi

2021 revenue: $17.
81 billion

2020 revenue: $11.
82 billion

Huizhi surpassed Teva and Sandoz to become the world's largest generic drug company
.
In 2021, Huizhi's first full fiscal year, revenue of $17.
81 billion was above the company's guidance of $17.
5 billion
.
Among them, the revenue of "branded" drugs was $10.
84 billion, the revenue of "specialty generics and biosimilars" was $1.
34 billion, and the revenue of standard "generic drugs" was $5.
63 billion
.

Huizhi was formed by the merger of generic drug giant Mylan and Pfizer's Upjohn divisions in November 2020.
By integrating the strengths of these two companies, Huizhi's product portfolio includes more than 1,400 approved molecules, covering a wide range of key therapeutic areas, including global Recognized iconic and key brand, generic, complex generic and biosimilar products
.
In terms of market segments, Huizhi performed strongly in China and Europe
.
For the full year of 2021, sales in Greater China reached US$2.
21 billion, an increase of 2% year-on-year, and accounted for 13% of Huizhi's total global revenue
.

References:

1.
The top 20 pharma companies by 2021 revenue

https://#90d4a10e-1681-4fa8-a574-9ec7ccc3c97b

2.
Corporate annual report